Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tenax Therapeutics, Inc. (TENX)
USD15.45
-0.11 (-0.74%)
US NASDAQ Healthcare Biotechnology
Address
ONE Copley Parkway 27560
Chapel Hill, NC, US
Chapel Hill, NC, US
CEO
Christopher T. Giordano
Website
tenaxthera.com
IPO
1994-04-04
CIK 34956 ISIN US88032L6056
Description
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD15.45
-0.11 (-0.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
795.7K
Beta
0.96
Float Shares
16.53M
Free Float %
96.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.84% | +3.22% | -16.07% | -3.79% | +81.91% | -0.16% | +114.64% | -54.18% | -99.62% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
15.45
Low
25.00
+61.9%
Consensus
25.00
+61.9%
Median
25.00
+61.9%
High
25.00
+61.9%
DCF (Unlevered)
2.35
-84.8%
DCF (Levered)
2.49
-83.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
20.00
+29.5%
|
| All Time | 4 |
20.00
+29.5%
|
Quality scores
Altman Z-Score
11.84
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-16.5% Q1'26: -25.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+156.8% Q1'26: +23.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 2.00M (-100.0%)
|
4.16M
4.16M – 4.16M
+107.8% YoY
|
12.90M
12.90M – 12.90M
+210.4% YoY
|
46.67M
46.67M – 46.67M
+261.8% YoY
|
144.00M
144.00M – 144.00M
+208.5% YoY
|
296.27M
296.27M – 296.27M
+105.7% YoY
|
| EBITDA |
-17.58M
|
-56.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-17.58M
|
-56.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-17.60M
est: -14.86M (-18.4%)
|
-52.60M
est: -54.03M (+2.6%)
|
-61.05M
-69.82M – -52.27M
-13.0% YoY
|
-59.63M
-69.57M – -49.69M
+2.3% YoY
|
-57.72M
-71.80M – 61.60M
+3.2% YoY
|
-40.00M
-40.00M – -40.00M
+30.7% YoY
|
7.53M
7.53M – 7.53M
+118.8% YoY
|
| SGA |
6.79M
|
23.71M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.15
est: -0.97 (-18.2%)
|
-1.34
est: -1.37 (+2.4%)
|
-1.56
-1.78 – -1.33
-13.4% YoY
|
-1.46
-1.77 – -1.27
+6.1% YoY
|
-1.07
-1.83 – 1.57
+27.0% YoY
|
-1.02
-1.02 – -1.02
+4.4% YoY
|
0.19
0.19 – 0.19
+118.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.86M
OE per share TTM
-877.91
Owner's Yield
-1.97%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,235.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
48
Total invested
84.70M
Insider transactions (90d)
0
Beneficial owners (>5%)
44
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Vivo Opportunity Fund Holdings, L.P. | 6.25M | 9.99% | 6.25M | — | 6.25M | — | PN | Delaware | 2024-08-14 | ↗ |
| 2 | Vivo Opportunity, LLC | 6.25M | 9.99% | 6.25M | — | 6.25M | — | OO | Delaware | 2024-08-14 | ↗ |
| 3 | Stuart Rich | 4.31M | 14.30% | 62.5K | 3.82M | 62.5K | 3.82M | IN | United States | 2022-09-23 | ↗ |
| 4 | 52-0556948 | 3.75M | 19.99% | — | — | 3.75M | — | IA | Maryland | 2024-09-10 | ↗ |
| 5 | Doogan | 3.64M | 14.44% | 3.64M | — | 3.37M | 11.00 | IN | — | 2021-06-22 | ↗ |
| 6 | Armistice Capital, LLC | 2.57M | 9.99% | — | 2.57M | — | 2.57M | IA, OO | Delaware | 2022-06-21 | ↗ |
| 7 | Steven Boyd | 2.57M | 9.99% | — | 2.57M | — | 2.57M | HC, IN | Delaware | 2022-06-21 | ↗ |
| 8 | Andrea Rich 2021 Irrevocable Trust | 1.91M | 6.40% | — | 1.91M | — | 1.91M | OO | United States | 2022-09-23 | ↗ |
| 9 | Stuart Rich 2022 Irrevocable Trust | 1.91M | 6.40% | — | 1.91M | — | 1.91M | OO | United States | 2022-09-23 | ↗ |
| 10 | 13-3127734 | 448.3K | 6.65% | 441.9K | — | 446.8K | 1.5K | HC | Delaware | 2020-02-13 | ↗ |
| 11 | Armistice Capital Master Fund Ltd. | 421.1K | 5.60% | — | 421.1K | — | 421.1K | CO | Delaware | 2020-03-23 | ↗ |
| 12 | Jeff Easton | 375.0K | 9.90% | 375.0K | — | 375.0K | — | IN | Delaware | 2024-11-14 | ↗ |
| 13 | Lind Global Fund II LP | 375.0K | 9.90% | 375.0K | — | 375.0K | — | PN | Delaware | 2024-11-14 | ↗ |
| 14 | Lind Global Partners II LLC | 375.0K | 9.90% | 375.0K | — | 375.0K | — | OO | Delaware | 2024-11-14 | ↗ |
| 15 | Jon M. Plexico | 372.8K | 11.00% | — | 372.8K | — | 372.8K | HC, IN | Delaware | 2024-08-15 | ↗ |
| 16 | Stonepine Capital Management, LLC | 372.8K | 11.00% | — | 372.8K | — | 372.8K | IA, OO | Delaware | 2024-08-15 | ↗ |
| 17 | Stonepine Capital, L.P. | 372.8K | 11.00% | — | 372.8K | — | 372.8K | PN | Delaware | 2024-08-15 | ↗ |
| 18 | Stonepine GP, LLC | 372.8K | 11.00% | — | 372.8K | — | 372.8K | OO | Delaware | 2024-08-15 | ↗ |
| 19 | Timothy P. Lynch | 372.8K | 11.00% | — | 372.8K | — | 372.8K | HC, IN | Delaware | 2024-08-15 | ↗ |
| 20 | Adage Capital Management, L.P. | 369.1K | 9.99% | — | 369.1K | — | — | IA, PN | Delaware | 2024-11-12 | ↗ |
| 21 | Phillip Gross | 369.1K | 9.99% | — | 369.1K | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 22 | Robert Atchinson | 369.1K | 9.99% | — | 369.1K | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 23 | 00-0000000 | 359.8K | 9.90% | — | 359.8K | — | 359.8K | CO | Jersey, Channel Islands | 2024-08-14 | ↗ |
| 24 | EIN #00-0000000 | 359.8K | 9.90% | — | 359.8K | — | 359.8K | IA, HC | Jersey, Channel Islands | 2024-08-14 | ↗ |
| 25 | Koh, Bong | 355.2K | 9.99% | — | 355.2K | — | 355.2K | IN | Delaware | 2024-08-19 | ↗ |
| 26 | Shah, Nimish | 355.2K | 9.99% | — | 355.2K | — | 355.2K | IN | Delaware | 2024-08-19 | ↗ |
| 27 | VHCP Co-Investment Holdings III, LLC | 355.2K | 9.99% | — | 355.2K | — | 355.2K | OO | Delaware | 2024-08-19 | ↗ |
| 28 | VHCP Management EG, LLC | 355.2K | 9.99% | — | 355.2K | — | 355.2K | OO | Delaware | 2024-08-19 | ↗ |
| 29 | VHCP Management III, LLC | 355.2K | 9.99% | — | 355.2K | — | 355.2K | OO | Delaware | 2024-08-19 | ↗ |
| 30 | Venrock Healthcare Capital Partners EG, L.P. | 355.2K | 9.99% | — | 355.2K | — | 355.2K | PN | Delaware | 2024-08-19 | ↗ |
| 31 | Venrock Healthcare Capital Partners III, L.P. | 355.2K | 9.99% | — | 355.2K | — | 355.2K | PN | Delaware | 2024-08-19 | ↗ |
| 32 | BVF Inc. | 340.7K | 9.99% | — | — | — | 340.7K | CO | Delaware | 2024-08-19 | ↗ |
| 33 | BVF Partners L.P. | 340.7K | 9.99% | — | — | — | 340.7K | IA, PN | Delaware | 2024-08-19 | ↗ |
| 34 | Mark N. Lampert | 340.7K | 9.99% | — | — | — | 340.7K | IN | Delaware | 2024-08-19 | ↗ |
| 35 | BVF GP Holdings LLC | 320.1K | 9.40% | — | — | — | 320.1K | OO | Delaware | 2024-08-19 | ↗ |
| 36 | CVI Investments, Inc. | 204.0K | 9.90% | — | 204.0K | — | 204.0K | CO | Cayman Islands | 2024-02-16 | ↗ |
| 37 | Heights Capital Management, Inc. | 204.0K | 9.90% | — | 204.0K | — | 204.0K | CO | Cayman Islands | 2024-02-16 | ↗ |
| 38 | BVF I GP LLC | 180.1K | 5.30% | — | — | — | 180.1K | OO | Delaware | 2024-08-19 | ↗ |
| 39 | Biotechnology Value Fund, L.P. | 180.1K | 5.30% | — | — | — | 180.1K | PN | Delaware | 2024-08-19 | ↗ |
| 40 | BVF II GP LLC | 140.1K | 4.10% | — | — | — | 140.1K | OO | Delaware | 2024-08-19 | ↗ |
| 41 | Biotechnology Value Fund II, L.P. | 140.1K | 4.10% | — | — | — | 140.1K | PN | Delaware | 2024-08-19 | ↗ |
| 42 | S.H.N. Financial Investments Ltd. | 107.0K | 5.60% | 107.0K | — | — | — | OO | Israel | 2024-02-20 | ↗ |
| 43 | BVF Partners OS Ltd. | 14.7K | 1.00% | — | — | — | 14.7K | CO | Delaware | 2024-08-19 | ↗ |
| 44 | Biotechnology Value Trading Fund OS LP | 14.7K | 1.00% | — | — | — | 14.7K | PN | Delaware | 2024-08-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
48
+14 vs prev Q
New positions
19
Closed positions
5
Increased
31
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | IKARIAN CAPITAL, LLC | 967.6K +— (+0.0%) | 11.80M +4.4M (+60.2%) | 2.43% -0.010 pp | 0.92% +0.177 pp | USD7.61 +60.2% | 2 qtrs — |
| 2 | MORGAN STANLEY | 596.4K +418.0K (+234.4%) | 7.27M +5.9M (+435.7%) | 1.50% +1.050 pp | 0.00% +0.000 pp | USD10.38 +17.4% | 8 qtrs — |
| 3 | PERCEPTIVE ADVISORS LLC | 439.1K +439.1K (+100.0%) | 5.35M +5.4M (+100.0%) | 1.11% +1.105 pp | 0.10% +0.095 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 4 | SIREN, L.L.C. | 427.1K +74.7K (+21.2%) | 5.21M +2.5M (+94.1%) | 1.07% +0.184 pp | 0.16% +0.050 pp | USD8.41 +44.9% | 2 qtrs — |
| 5 | POINT72 ASSET MANAGEMENT, L.P. | 423.4K +423.4K (+100.0%) | 5.16M +5.2M (+100.0%) | 1.07% +1.065 pp | 0.01% +0.006 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 6 | RTW INVESTMENTS, LP | 378.3K +— (+0.0%) | 4.61M +1.7M (+60.2%) | 0.95% -0.004 pp | 0.05% +0.011 pp | USD6.55 +86.1% | 4 qtrs — |
| 7 | BOOTHBAY FUND MANAGEMENT, LLC | 352.2K +— (+0.0%) | 4.29M +1.6M (+60.2%) | 0.89% -0.004 pp | 0.06% +0.025 pp | USD7.61 +60.2% | 2 qtrs — |
| 8 | BVF INC/IL | 339.5K +— (+0.0%) | 4.14M +1.6M (+60.2%) | 0.85% -0.004 pp | 0.14% +0.035 pp | USD3.46 +252.3% | 6 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 302.5K -11.2K (-3.6%) | 3.69M +1.3M (+54.4%) | 0.76% -0.032 pp | 0.00% +0.001 pp | USD6.27 +94.4% | 5 qtrs — |
| 10 | MARSHALL WACE, LLP | 298.2K +120.9K (+68.2%) | 3.63M +2.3M (+169.5%) | 0.75% +0.302 pp | 0.00% +0.002 pp | USD9.47 +28.7% | 2 qtrs — |
| 11 | VANGUARD GROUP INC | 255.7K +93.9K (+58.0%) | 3.12M +1.9M (+153.1%) | 0.64% +0.234 pp | 0.00% +0.000 pp | USD9.17 +32.9% | 5 qtrs — |
| 12 | DIADEMA PARTNERS LP | 243.2K +243.2K (+100.0%) | 2.96M +3.0M (+100.0%) | 0.61% +0.612 pp | 0.51% +0.511 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 13 | VIVO CAPITAL, LLC | 208.3K +— (+0.0%) | 2.54M +954.2K (+60.2%) | 0.52% -0.002 pp | 0.16% +0.037 pp | USD3.46 +252.3% | 6 qtrs — |
| 14 | SPHERA FUNDS MANAGEMENT LTD. | 190.1K +190.1K (+100.0%) | 2.32M +2.3M (+100.0%) | 0.48% +0.478 pp | 0.45% +0.448 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 15 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 167.0K +— (+0.0%) | 2.04M +764.9K (+60.2%) | 0.42% -0.002 pp | 0.10% +0.015 pp | USD6.55 +86.1% | 4 qtrs — |
| 16 | JANUS HENDERSON GROUP PLC | 166.7K +— (+0.0%) | 2.02M +745.8K (+58.6%) | 0.42% -0.002 pp | 0.00% +0.000 pp | USD6.19 +96.9% | 5 qtrs — |
| 17 | WOODLINE PARTNERS LP | 143.5K +55.3K (+62.7%) | 1.75M +1.1M (+160.5%) | 0.36% +0.138 pp | 0.01% +0.004 pp | USD9.37 +30.1% | 2 qtrs — |
| 18 | FMR LLC | 141.1K +141.1K (+100.0%) | 1.72M +1.7M (+100.0%) | 0.36% +0.355 pp | 0.00% +0.000 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 19 | CITADEL ADVISORS LLC | 129.5K +86.3K (+199.5%) | 1.58M +1.2M (+379.7%) | 0.33% +0.217 pp | 0.00% +0.000 pp | USD10.58 +15.2% | 4 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 125.6K +69.0K (+121.9%) | 1.53M +1.1M (+255.4%) | 0.32% +0.173 pp | 0.00% +0.002 pp | USD10.13 +20.3% | 2 qtrs — |
| 21 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 83.3K +— (+0.0%) | 1.02M +381.7K (+60.2%) | 0.21% -0.001 pp | 0.59% -0.006 pp | USD3.46 +252.3% | 6 qtrs — |
| 22 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 83.3K +— (+0.0%) | 1.02M +381.7K (+60.2%) | 0.21% -0.001 pp | 0.00% +0.001 pp | USD3.46 +252.3% | 6 qtrs — |
| 23 | PERSISTENT ASSET PARTNERS LTD | 65.3K +65.3K (+100.0%) | 795.7K +795.7K (+100.0%) | 0.16% +0.164 pp | 0.36% +0.357 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 24 | ADAR1 CAPITAL MANAGEMENT, LLC | 63.7K +10.2K (+19.2%) | 776.2K +369.6K (+90.9%) | 0.16% +0.025 pp | 0.06% +0.019 pp | USD6.51 +87.3% | 6 qtrs — |
| 25 | GEODE CAPITAL MANAGEMENT, LLC | 55.7K +21.3K (+61.8%) | 679.0K +417.0K (+159.2%) | 0.14% +0.053 pp | 0.00% +0.000 pp | USD7.55 +61.5% | 7 qtrs — |
| 26 | VESTAL POINT CAPITAL, LP | 53.4K +— (+0.0%) | 651.4K +244.8K (+60.2%) | 0.13% -0.001 pp | 0.02% +0.004 pp | USD3.46 +252.3% | 6 qtrs — |
| 27 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 44.9K +44.9K (+100.0%) | 547.3K +547.3K (+100.0%) | 0.11% +0.113 pp | 0.01% +0.012 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 28 | ARTIA GLOBAL PARTNERS LP | 42.1K +42.1K (+100.0%) | 513.0K +513.0K (+100.0%) | 0.11% +0.106 pp | 0.08% +0.082 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 29 | TWO SIGMA INVESTMENTS, LP | 33.5K +33.5K (+100.0%) | 408.0K +408.0K (+100.0%) | 0.08% +0.084 pp | 0.00% +0.001 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 30 | GOLDMAN SACHS GROUP INC | 22.4K +22.4K (+100.0%) | 273.2K +273.2K (+100.0%) | 0.06% +0.056 pp | 0.00% +0.000 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 31 | QUADRATURE CAPITAL LTD | 20.6K +20.6K (+100.0%) | 251.7K +251.7K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.003 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 32 | BLACKROCK, INC. | 16.7K +16.4K (+5,452.8%) | 203.7K +201.5K (+8,793.2%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD12.03 +1.3% | 6 qtrs — |
| 33 | BNP PARIBAS ARBITRAGE, SNC | 15.3K +15.3K (+100.0%) | 186.5K +186.5K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 34 | TWO SIGMA ADVISERS, LP | 13.2K +13.2K (+100.0%) | 160.6K +160.6K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 35 | CI PRIVATE WEALTH, LLC | 12.4K +12.4K (+100.0%) | 151.0K +151.0K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 36 | STONEPINE CAPITAL MANAGEMENT, LLC | 11.9K +11.9K (+100.0%) | 144.9K +144.9K (+100.0%) | 0.03% +0.030 pp | 0.11% +0.106 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 37 | LETKO, BROSSEAU & ASSOCIATES INC | 10.7K +10.7K (+100.0%) | 129.8K +129.8K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.002 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 38 | BANK OF AMERICA CORP /DE/ | 3.8K +3.5K (+1,388.2%) | 46.1K +44.1K (+2,283.8%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD11.78 +3.5% | 7 qtrs — |
| 39 | JPMORGAN CHASE & CO | 902.00 +902.0 (+100.0%) | 11.0K +11.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD12.19 +0.0% | 1 qtrs NEW |
| 40 | UBS GROUP AG | 676.00 +557.0 (+468.1%) | 8.2K +7.3K (+809.5%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.36 +7.3% | 8 qtrs — |
| 41 | TOWER RESEARCH CAPITAL LLC (TRC) | 199.00 -302.0 (-60.3%) | 2.4K -1.4K (-36.4%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD5.88 +107.3% | 8 qtrs — |
| 42 | ALLWORTH FINANCIAL LP | 1.00 +— (+0.0%) | 13.00 +5.0 (+62.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 +306.3% | 8 qtrs — |
| 43 | PHYSICIAN WEALTH ADVISORS, INC. | 1.00 +— (+0.0%) | 13.00 +5.0 (+62.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.00 +103.2% | 5 qtrs — |
| 44 | JONES FINANCIAL COMPANIES LLLP | 1.00 +— (+0.0%) | 12.00 +5.0 (+71.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.00 +143.8% | 3 qtrs — |
| 45 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 1.00 -1.0 (-50.0%) | 12.00 -3.0 (-20.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.00 +74.1% | 2 qtrs — |
| 46 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 12.00 +12.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.00 +1.6% | 1 qtrs NEW |
| 47 | UNION BANCAIRE PRIVEE, UBP SA | 1.00 +— (+0.0%) | 9.00 +3.0 (+50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.00 +103.2% | 5 qtrs — |
| 48 | DRW SECURITIES, LLC | — -10.5K (-100.0%) | — -80.0K (-100.0%) | 0.00% -0.027 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 49 | VIRTU FINANCIAL LLC | — -12.1K (-100.0%) | — -92.0K (-100.0%) | 0.00% -0.031 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 50 | VR ADVISER, LLC | — -437.7K (-100.0%) | — -3.3M (-100.0%) | 0.00% -1.106 pp | 0.00% -0.188 pp | USD— | 6 qtrs SOLD |
| 51 | WEALTHSPIRE ADVISORS, LLC | — -1.0 (-100.0%) | — -8.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 52 | SBI SECURITIES CO., LTD. | — -2.0 (-100.0%) | — -15.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 44 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.24% | 508.4K | 0.50% |
| 2 | iShares Micro-Cap ETF IWC | 0.10% | 1.49M | 0.60% |
| 3 | T. Rowe Price Innovation Leaders ETF TNXT | 0.04% | 7.7K | 0.49% |
| 4 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 294.7K | 0.20% |
| 5 | iShares Russell 2000 Value ETF IWN | 0.03% | 4.00M | 0.24% |
| 6 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.02% | 904.0K | 0.30% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 8.0K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.01% | 11.71M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 76.5K | 0.36% |
| 10 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 44.7K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
13
Sells
0
Shares acquired
22.6K
Shares disposed
—
Cash buys
13.00
Cash sales
—
Net activity
+22,598
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | MCGAULEY THOMAS | Officer | M-Exempt | A | Stock Option (right to buy) | 50,000 | 12.51 | 625.5K | 50,000 | D | ↗ |
| 2026-01-09 | Rich Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 13.30 | 3.33M | 250,000 | D | ↗ |
| 2026-01-09 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 13.30 | 39.9K | 30,000 | D | ↗ |
| 2026-01-09 | Hunter Robyn | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 13.30 | 399.0K | 30,000 | D | ↗ |
| 2026-01-09 | Giordano Christopher Thomas | Director / Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 13.30 | 5.99M | 450,000 | D | ↗ |
| 2026-01-09 | Doogan Declan | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 13.30 | 399.0K | 30,000 | D | ↗ |
| 2026-01-09 | Davidson Michael H. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 13.30 | 399.0K | 30,000 | D | ↗ |
| 2026-01-09 | Almenoff June Sherie | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 13.30 | 399.0K | 30,000 | D | ↗ |
| 2025-12-09 | Rich Stuart | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 10.22 | 25.5K | 5,266 | D | ↗ |
| 2025-12-08 | Rich Stuart | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 10.10 | 25.3K | 5,000 | I | ↗ |
| 2025-12-04 | Rich Stuart | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 9.20 | 23.0K | 2,500 | I | ↗ |
| 2025-12-03 | Rich Stuart | Director / Officer | P-Purchase | A | Common Stock | 1,500 | 9.08 | 13.6K | 2,766 | D | ↗ |
| 2025-12-02 | Rich Stuart | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 9.01 | 9.0K | 1,266 | D | ↗ |
| 2025-11-20 | Giordano Christopher Thomas | Director / Officer | P-Purchase | A | Common Stock | 538 | 7.59 | 4.1K | 2,605 | D | ↗ |
| 2025-11-19 | Giordano Christopher Thomas | Director / Officer | P-Purchase | A | Common Stock | 455 | 7.51 | 3.4K | 2,067 | D | ↗ |
| 2025-11-18 | Giordano Christopher Thomas | Director / Officer | P-Purchase | A | Common Stock | 1,612 | 7.75 | 12.5K | 1,612 | D | ↗ |
| 2025-11-18 | Almenoff June Sherie | Director | P-Purchase | A | Common Stock | 1,900 | 7.52 | 14.3K | 1,993 | D | ↗ |
| 2025-11-17 | MCGAULEY THOMAS | Officer | P-Purchase | A | Common Stock | 5,000 | 7.23 | 36.1K | 5,000 | I | ↗ |
| 2025-11-17 | Almenoff June Sherie | Director | P-Purchase | A | Common Stock | 93 | 7.15 | 664.95 | 93 | D | ↗ |
| 2025-07-01 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 5.75 | 460.0K | 80,000 | D | ↗ |
| 2025-07-01 | Hunter Robyn | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 5.75 | 460.0K | 80,000 | D | ↗ |
| 2025-07-01 | Doogan Declan | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 5.75 | 460.0K | 80,000 | D | ↗ |
| 2025-07-01 | Davidson Michael H. | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 5.75 | 460.0K | 80,000 | D | ↗ |
| 2025-07-01 | Almenoff June Sherie | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 5.75 | 460.0K | 80,000 | D | ↗ |
| 2025-05-16 | Rich Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 625,000 | 5.89 | 3.68M | 625,000 | D | ↗ |
| 2025-05-16 | Giordano Christopher Thomas | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,400,000 | 5.89 | 8.25M | 1,400,000 | D | ↗ |
| 2025-03-05 | Dellora Investments LP | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-08 | Dellora Investments LP | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 351,071 | I | ↗ |
| 2024-12-10 | Rich Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 5.94 | 2.97M | 500,000 | D | ↗ |
| 2024-12-10 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 5.94 | 594.0K | 100,000 | D | ↗ |
| 2024-12-10 | Hunter Robyn | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 5.94 | 594.0K | 100,000 | D | ↗ |
| 2024-12-10 | Giordano Christopher Thomas | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,250,000 | 5.94 | 7.43M | 1,250,000 | D | ↗ |
| 2024-12-10 | Doogan Declan | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 5.94 | 594.0K | 100,000 | D | ↗ |
| 2024-12-10 | Davidson Michael H. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 5.94 | 594.0K | 100,000 | D | ↗ |
| 2024-12-10 | Almenoff June Sherie | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 5.94 | 594.0K | 100,000 | D | ↗ |
| 2024-12-02 | MCGAULEY THOMAS | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-08-08 | PROEHL GERALD T | Director | P-Purchase | A | Common Stock | 1,666 | 3.00 | 5.0K | 1,667 | — | ↗ |
| 2024-08-08 | Davidson Michael H. | Director | P-Purchase | A | Warrant | 25,000 | 4.50 | 112.5K | 25,000 | — | ↗ |
| 2024-05-17 | Rich Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 119 | 3.55 | 422.33 | 119 | — | ↗ |
| 2024-05-17 | Giordano Christopher Thomas | Director / Officer | A-Award | A | Stock Option (right to buy) | 437 | 3.55 | 1.6K | 437 | — | ↗ |
| 2024-01-11 | HOFFMAN LAWRENCE R | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-21 | Rich Stuart | Director / Officer / 10% Owner | G-Gift | A | Common Stock | 1,909,585 | 0.00 | — | 1,909,585 | — | ↗ |
| 2022-08-11 | Doogan Declan | Director | G-Gift | D | Common Stock | 567,871 | 0.00 | — | 0 | — | ↗ |
| 2022-06-09 | Rich Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-09 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.62 | 3.1K | 5,000 | — | ↗ |
| 2022-06-09 | Hunter Robyn | Director | A-Award | A | Stock Option (right to buy) | 6,250 | 0.00 | — | 6,250 | — | ↗ |
| 2022-06-09 | Giordano Christopher Thomas | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-06-09 | Doogan Declan | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2022-06-09 | Davidson Michael H. | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.62 | 3.1K | 5,000 | — | ↗ |
| 2022-06-09 | Almenoff June Sherie | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 0.62 | 3.1K | 5,000 | — | ↗ |
| 2022-05-18 | Boyd Steven | Director | A-Award | A | Series C Common Stock Purchase Warrants | 10,596,027 | 0.00 | — | 10,596,027 | — | ↗ |
| 2022-01-28 | Hunter Robyn | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-29 | Rich Stuart | Director / Officer / 10% Owner | G-Gift | D | Common stock | 1,909,585 | 0.00 | — | 0 | — | ↗ |
| 2021-10-29 | Lurier Eliot M | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-12 | Rich Stuart | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 1,909,585 | 0.00 | — | 2,333,932 | — | ↗ |
| 2021-07-14 | Giordano Chrisopher Thomas | Director / Officer | — | D | Stock Option (right to buy) | 250,000 | 1.97 | 492.5K | 0 | — | ↗ |
| 2021-07-08 | ARMISTICE CAPITAL, LLC | Director | A-Award | A | Warrant (right to buy) | 4,773,269 | 1.97 | 9.40M | 4,773,269 | — | ↗ |
| 2021-07-06 | DiTonno Anthony A | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 1.97 | 98.5K | 50,000 | — | ↗ |
| 2021-06-30 | Doogan Declan | Director / 10% Owner | G-Gift | D | Common Stock | 567,871 | 0.00 | — | 2,502,129 | — | ↗ |
| 2021-06-11 | Rich Stuart | Director / Officer / 10% Owner | M-Exempt | D | Series B Preferred Stock | 3,581 | 0.00 | — | 0 | — | ↗ |
| 2021-06-11 | Doogan Declan | Director / 10% Owner | M-Exempt | D | Series B Preferred Stock | 3,070 | 0.00 | — | 0 | — | ↗ |
| 2021-06-11 | Davidson Michael H. | Director | A-Award | A | Common Stock | 512,000 | 0.00 | — | 606,645 | — | ↗ |
| 2021-06-10 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 2.00 | 10.0K | 5,000 | — | ↗ |
| 2021-06-10 | Mitchum James P. | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 2.00 | 10.0K | 5,000 | — | ↗ |
| 2021-06-10 | Doogan Declan | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,250 | 2.00 | 12.5K | 6,250 | — | ↗ |
| 2021-06-10 | Davidson Michael H. | Director | A-Award | A | Stock Option (right to buy) | 6,250 | 2.00 | 12.5K | 6,250 | — | ↗ |
| 2021-06-10 | Almenoff June Sherie | Director | A-Award | A | Stock Option (right to buy) | 6,250 | 2.00 | 12.5K | 6,250 | — | ↗ |
| 2021-02-25 | Doogan Declan | Director | — | D | Series B Preferred Stock | 0 | 0.00 | — | 3,070 | — | ↗ |
| 2021-02-25 | Davidson Michael H. | Director | — | D | Common Stock | 0 | 0.00 | — | 96,645 | — | ↗ |
| 2021-02-25 | Almenoff June Sherie | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-15 | Rich Stuart | Officer | A-Award | A | Common Stock | 662,517 | 0.00 | — | 662,517 | — | ↗ |
| 2021-01-05 | Jebsen Michael B | Officer | A-Award | A | Stock option (right to buy) | 70,000 | 1.85 | 129.5K | 70,000 | — | ↗ |
| 2021-01-05 | DiTonno Anthony A | Director / Officer | A-Award | A | Stock option (right to buy) | 90,000 | 1.85 | 166.5K | 90,000 | — | ↗ |
| 2020-09-08 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 8,543 | 1.46 | 12.5K | 2,019,995 | — | ↗ |
| 2020-09-04 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 23,457 | 1.41 | 33.1K | 2,011,452 | — | ↗ |
| 2020-09-03 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 36,000 | 1.39 | 50.0K | 1,987,995 | — | ↗ |
| 2020-09-02 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 0 | 0.00 | — | 1,951,995 | — | ↗ |
| 2020-09-01 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 0 | 0.00 | — | 1,931,995 | — | ↗ |
| 2020-08-31 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 0 | 0.00 | — | 1,901,995 | — | ↗ |
| 2020-08-27 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 12,000 | 1.50 | 18.0K | 1,881,995 | — | ↗ |
| 2020-08-26 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 12,000 | 1.50 | 18.0K | 1,869,995 | — | ↗ |
| 2020-08-25 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 17,211 | 1.53 | 26.3K | 1,857,995 | — | ↗ |
| 2020-08-24 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 0 | 0.00 | — | 1,840,784 | — | ↗ |
| 2020-08-21 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 116,242 | 1.44 | 167.4K | 1,835,092 | — | ↗ |
| 2020-08-20 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 124,472 | 1.53 | 190.4K | 1,718,850 | — | ↗ |
| 2020-08-19 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 70,767 | 1.45 | 102.6K | 1,594,378 | — | ↗ |
| 2020-07-20 | Maher Illya Keith | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-06 | ARMISTICE CAPITAL, LLC | 10% Owner | — | I | Series B Common Stock Purchase Warrants | 3,175,924 | 0.90 | 2.87M | 0 | — | ↗ |
| 2020-05-18 | BLANCK RONALD R | Director | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 6,062 | — | ↗ |
| 2020-05-01 | RALLIS CHRIS A | Director | A-Award | A | Stock Option (right to buy) | 500 | 0.66 | 330.00 | 500 | — | ↗ |
| 2020-05-01 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 500 | 0.66 | 330.00 | 500 | — | ↗ |
| 2020-05-01 | Mitchum James P. | Director | A-Award | A | Stock Option (right to buy) | 500 | 0.66 | 330.00 | 500 | — | ↗ |
| 2020-05-01 | BLANCK RONALD R | Director | A-Award | A | Stock Option (right to buy) | 500 | 0.66 | 330.00 | 500 | — | ↗ |
| 2020-03-13 | ARMISTICE CAPITAL, LLC | 10% Owner | — | I | Common Stock Purchase Warrants | 2,360,313 | 1.04 | 2.45M | 0 | — | ↗ |
| 2020-03-01 | Jebsen Michael B | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2020-03-01 | DiTonno Anthony A | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2019-05-01 | RALLIS CHRIS A | Director | A-Award | A | Stock Option (right to buy) | 500 | 1.72 | 860.00 | 500 | — | ↗ |
| 2018-12-11 | ARMISTICE CAPITAL, LLC | 10% Owner | — | D | Common Stock Purchase Warrants | 2,072,538 | 1.93 | 4.00M | 0 | — | ↗ |
| 2018-07-31 | Jebsen Michael B | Officer | D-Return | A | common stock | 5,720 | 6.25 | 35.8K | 34,680 | — | ↗ |
| 2018-06-01 | DiTonno Anthony A | Director / Officer | A-Award | A | Stock option (right to buy) | 50,000 | 6.10 | 305.0K | 50,000 | — | ↗ |
| 2018-05-01 | PROEHL GERALD T | Director | A-Award | A | Stock Option (right to buy) | 500 | 6.23 | 3.1K | 500 | — | ↗ |
| 2018-05-01 | Mitchum James P. | Director | A-Award | A | Stock Option (right to buy) | 500 | 6.23 | 3.1K | 500 | — | ↗ |
| 2018-05-01 | DiTonno Anthony A | Director | A-Award | A | Stock Option (right to buy) | 500 | 6.23 | 3.1K | 500 | — | ↗ |
| 2018-05-01 | BLANCK RONALD R | Director | A-Award | A | Stock Option (right to buy) | 500 | 6.23 | 3.1K | 500 | — | ↗ |
| 2018-03-30 | Jebsen Michael B | Officer | D-Return | A | common stock | 6,425 | 5.42 | 34.8K | 12,310 | — | ↗ |
| 2017-12-29 | Jebsen Michael B | Officer | D-Return | A | common stock | 98 | 0.43 | 42.14 | 68,264 | — | ↗ |
| 2017-12-18 | BLANCK RONALD R | Director | P-Purchase | A | Common Stock | 6,475 | 0.45 | 2.9K | 20,099 | — | ↗ |
| 2017-11-14 | BLANCK RONALD R | Director | S-Sale | D | Common Stock | 12,950 | 0.39 | 5.1K | 7,149 | — | ↗ |
| 2017-07-31 | Jebsen Michael B | Officer | D-Return | A | common stock | 54 | 0.65 | 35.10 | 68,146 | — | ↗ |
| 2017-04-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 56 | 0.54 | 30.24 | 68,200 | — | ↗ |
| 2017-04-03 | Jebsen Michael B | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.53 | 106.0K | 200,000 | — | ↗ |
| 2017-03-15 | Kelley John P | Director / Officer | A-Award | A | Common Stock | 213,420 | 0.00 | — | 1,379,931 | — | ↗ |
| 2016-12-19 | Jebsen Michael B | Officer | D-Return | A | common stock | 49 | 2.07 | 101.43 | 68,256 | — | ↗ |
| 2016-12-15 | Kelley John P | Director / Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 2.07 | 248.4K | 120,000 | — | ↗ |
| 2016-12-15 | Jebsen Michael B | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 2.07 | 310.5K | 150,000 | — | ↗ |
| 2016-11-23 | PROEHL GERALD T | Director | P-Purchase | A | Common Stock | 14,449 | 1.76 | 25.4K | 29,882 | — | ↗ |
| 2016-11-22 | PROEHL GERALD T | Director | P-Purchase | A | Common Stock | 15,433 | 1.59 | 24.5K | 15,433 | — | ↗ |
| 2016-11-21 | Mitchum James P. | Director | D-Return | A | common stock | 7,000 | 1.51 | 10.6K | 26,000 | — | ↗ |
| 2016-09-30 | Jebsen Michael B | Officer | D-Return | D | common stock | 49 | 2.32 | 113.68 | 68,305 | — | ↗ |
| 2016-08-19 | RALLIS CHRIS A | Director | D-Return | A | common stock | 10,000 | 2.50 | 25.0K | 14,490 | — | ↗ |
| 2016-06-01 | Jebsen Michael B | Officer | D-Return | D | common stock | 55 | 2.72 | 149.60 | 68,354 | — | ↗ |
| 2016-05-23 | BLANCK RONALD R | Director | D-Return | A | common stock | 3,500 | 2.62 | 9.2K | 20,099 | — | ↗ |
| 2016-05-01 | Jebsen Michael B | Officer | A-Award | A | common stock | 430 | 2.72 | 1.2K | 68,409 | — | ↗ |
| 2016-02-03 | Mitchum James P. | Director | P-Purchase | A | Common Stock | 13,900 | 2.65 | 36.8K | 19,000 | — | ↗ |
| 2016-02-02 | Mitchum James P. | Director | P-Purchase | A | Common Stock | 5,100 | 2.68 | 13.7K | 5,100 | — | ↗ |
| 2016-02-02 | BLANCK RONALD R | Director | D-Return | A | common stock | 1,800 | 2.69 | 4.8K | 16,599 | — | ↗ |
| 2016-01-29 | Jebsen Michael B | Officer | D-Return | A | common stock | 56 | 2.65 | 148.40 | 67,979 | — | ↗ |
| 2015-11-19 | BLANCK RONALD R | Director | P-Purchase | A | common stock | 1,900 | 3.20 | 6.1K | 14,799 | — | ↗ |
| 2015-10-31 | Jebsen Michael B | Officer | D-Return | A | common stock | 49 | 3.19 | 156.31 | 68,035 | — | ↗ |
| 2015-09-15 | Mitchum James P. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-31 | Jebsen Michael B | Officer | D-Return | A | common stock | 49 | 3.68 | 180.32 | 68,084 | — | ↗ |
| 2015-05-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 430 | 3.42 | 1.5K | 68,133 | — | ↗ |
| 2015-02-13 | Jebsen Michael B | Officer | D-Return | A | Common Stock | 56 | 3.28 | 183.68 | 67,758 | — | ↗ |
| 2015-01-20 | BLANCK RONALD R | Director | P-Purchase | A | Common Stock | 2,000 | 3.49 | 7.0K | 10,199 | — | ↗ |
| 2014-10-31 | Jebsen Michael B | Officer | D-Return | A | Common Stock | 49 | 3.94 | 193.06 | 67,814 | — | ↗ |
| 2014-07-31 | Jebsen Michael B | Officer | D-Return | A | Common Stock | 50 | 3.91 | 195.50 | 67,863 | — | ↗ |
| 2014-07-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14,761 | 4.67 | 68.9K | 67,483 | — | ↗ |
| 2014-05-01 | Jebsen Michael B | Officer | A-Award | A | common stock | 430 | 4.98 | 2.1K | 67,913 | — | ↗ |
| 2014-04-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 15 | 5.55 | 83.25 | 82,244 | — | ↗ |
| 2014-04-03 | PROEHL GERALD T | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-03-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 16 | 6.47 | 103.52 | 82,259 | — | ↗ |
| 2014-02-15 | Jebsen Michael B | Officer | D-Return | A | Common stock | 16 | 6.18 | 98.88 | 50,132 | — | ↗ |
| 2014-01-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 16 | 4.50 | 72.00 | 50,148 | — | ↗ |
| 2013-12-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 6.27 | 87.78 | 50,164 | — | ↗ |
| 2013-11-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 3.04 | 42.56 | 50,178 | — | ↗ |
| 2013-11-13 | Kelley John P | Officer | A-Award | A | Series E Preferred Stock | 8,248 | 0.00 | — | 8,248 | — | ↗ |
| 2013-11-13 | Jebsen Michael B | Officer | A-Award | A | common stock | 32,143 | 7.00 | 225.0K | 82,335 | — | ↗ |
| 2013-10-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 1.47 | 20.58 | 50,192 | — | ↗ |
| 2013-10-04 | Jebsen Michael B | Officer | A-Award | A | common stock | 79,546 | 1.32 | 105.0K | 50,206 | — | ↗ |
| 2013-09-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 1.32 | 18.48 | 1,621 | — | ↗ |
| 2013-08-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 1.59 | 22.26 | 1,635 | — | ↗ |
| 2013-07-23 | RALLIS CHRIS A | Director | P-Purchase | A | Series C 8% Convertible Preferred Stock | 5 | 1.95 | 9.75 | 5 | — | ↗ |
| 2013-07-23 | DiTonno Anthony A | Director | P-Purchase | A | Series C 8% Convertible Preferred Stock | 5 | 1.95 | 9.75 | 5 | — | ↗ |
| 2013-07-23 | BLANCK RONALD R | Director | P-Purchase | A | Series C 8% Convertible Preferred Stock | 10 | 1.95 | 19.50 | 10 | — | ↗ |
| 2013-07-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 2.96 | 41.44 | 1,649 | — | ↗ |
| 2013-06-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 14 | 3.73 | 52.22 | 1,663 | — | ↗ |
| 2013-05-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 0.25 | 69.75 | 33,534 | — | ↗ |
| 2013-05-01 | Jebsen Michael B | Officer | A-Award | A | common stock | 8,600 | 0.25 | 2.2K | 33,813 | — | ↗ |
| 2013-04-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 322 | 0.25 | 80.50 | 25,213 | — | ↗ |
| 2013-03-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 324 | 0.28 | 90.72 | 25,535 | — | ↗ |
| 2013-02-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 324 | 0.68 | 220.32 | 25,859 | — | ↗ |
| 2013-01-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 324 | 0.64 | 207.36 | 26,183 | — | ↗ |
| 2012-12-01 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 0.69 | 192.51 | 26,507 | — | ↗ |
| 2012-11-01 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 1.05 | 292.95 | 26,786 | — | ↗ |
| 2012-10-01 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 0.60 | 167.40 | 27,065 | — | ↗ |
| 2012-09-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 0.88 | 245.52 | 27,344 | — | ↗ |
| 2012-08-31 | Jebsen Michael B | Officer | A-Award | A | common stock | 14,938 | 1.84 | 27.5K | 27,623 | — | ↗ |
| 2012-08-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 1.07 | 298.53 | 12,685 | — | ↗ |
| 2012-07-01 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 1.57 | 438.03 | 12,964 | — | ↗ |
| 2012-06-01 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 2.01 | 560.79 | 13,243 | — | ↗ |
| 2012-05-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 279 | 1.78 | 496.62 | 13,522 | — | ↗ |
| 2012-05-01 | RALLIS CHRIS A | Director | A-Award | A | common stock | 18,680 | 1.78 | 33.3K | 25,773 | — | ↗ |
| 2012-05-01 | Jebsen Michael B | Officer | A-Award | A | common stock | 8,600 | 1.78 | 15.3K | 13,801 | — | ↗ |
| 2012-05-01 | DiTonno Anthony A | Director | A-Award | A | Incentive Stock Options | 25,391 | 1.78 | 45.2K | 35,200 | — | ↗ |
| 2012-05-01 | Chatfield William A. | Director | A-Award | A | common stock | 18,961 | 1.78 | 33.8K | 42,289 | — | ↗ |
| 2012-05-01 | BLANCK RONALD R | Director | A-Award | A | Common stock | 18,961 | 1.78 | 33.8K | 43,479 | — | ↗ |
| 2012-04-15 | Jebsen Michael B | Officer | D-Return | A | common stock | 307 | 2.35 | 721.45 | 5,201 | — | ↗ |
| 2012-03-15 | Jebsen Michael B | Officer | D-Return | A | Common stock | 309 | 2.69 | 831.21 | 5,508 | — | ↗ |
| 2012-02-15 | Jebsen Michael B | Officer | D-Return | A | Common stock | 309 | 2.00 | 618.00 | 5,817 | — | ↗ |
| 2012-01-15 | Jebsen Michael B | Officer | D-Return | A | Common stock | 309 | 1.43 | 441.87 | 6,126 | — | ↗ |
| 2011-12-16 | RALLIS CHRIS A | Director | — | D | Common stock | 0 | 0.00 | — | 7,073 | — | ↗ |
| 2011-12-16 | DiTonno Anthony A | Director | — | D | Incentive Stock Options | 9,809 | 1.90 | 18.6K | 0 | — | ↗ |
| 2011-12-15 | Jebsen Michael B | Officer | D-Return | A | Common stock | 279 | 1.91 | 532.89 | 6,435 | — | ↗ |
| 2011-11-15 | Jebsen Michael B | Officer | D-Return | A | Common stock | 279 | 2.11 | 588.69 | 6,714 | — | ↗ |
| 2011-11-01 | BLANCK RONALD R | Director | A-Award | A | Common stock | 9,538 | 2.11 | 20.1K | 17,028 | — | ↗ |
| 2011-10-14 | Klein Gerald L | Officer | F-InKind | D | Common stock | 243 | 2.09 | 507.87 | 13,542 | — | ↗ |
| 2011-10-14 | Jebsen Michael B | Officer | F-InKind | D | Common stock | 279 | 2.09 | 583.11 | 6,993 | — | ↗ |
| 2011-09-12 | Klein Gerald L | Officer | F-InKind | D | Common stock | 243 | 2.28 | 554.04 | 13,785 | — | ↗ |
| 2011-09-12 | Jebsen Michael B | Officer | F-InKind | D | Common stock | 279 | 2.28 | 636.12 | 7,272 | — | ↗ |
| 2011-08-10 | Stern Christian J | Director / Officer | F-InKind | D | Common stock | 643 | 2.47 | 1.6K | 147,607 | — | ↗ |
| 2011-08-10 | Klein Gerald L | Officer | F-InKind | D | Common stock | 243 | 2.47 | 600.21 | 14,028 | — | ↗ |
| 2011-08-10 | Jebsen Michael B | Officer | F-InKind | D | Common stock | 279 | 2.47 | 689.13 | 7,551 | — | ↗ |
| 2011-08-05 | Jebsen Michael B | Officer | F-InKind | D | Common stock | 279 | 1.77 | 493.83 | 8,388 | — | ↗ |
| 2011-08-04 | Stern Christian J | Director / Officer | F-InKind | D | Common stock | 4,470 | 2.99 | 13.4K | 148,250 | — | ↗ |
| 2011-08-04 | Klein Gerald L | Officer | F-InKind | D | Common stock | 243 | 1.98 | 481.14 | 14,757 | — | ↗ |
| 2011-06-24 | BLANCK RONALD R | Director | A-Award | A | Common stock | 7,490 | 2.52 | 18.9K | 7,490 | — | ↗ |
| 2011-05-27 | Stern Christian J | Director / Officer | A-Award | A | Common Stock | 116,800 | 0.00 | — | 156,697 | — | ↗ |
| 2011-05-27 | Klein Gerald L | Officer | A-Award | A | COMMON STOCK | 7,500 | 0.00 | — | 15,000 | — | ↗ |
| 2011-05-27 | Jebsen Michael B | Officer | A-Award | A | COMMON STOCK | 8,600 | 0.00 | — | 8,667 | — | ↗ |
| 2011-05-13 | Klein Gerald L | Officer | A-Award | A | EMPLOYEE STOCK OPTION | 40,000 | 1.81 | 72.4K | 40,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
17.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Christopher T. Giordano President and Chief Executive Officer | 563.7K | — | — | 7.27M | 204.4K | 45.5K | 8.08M | 89.93% | ↗ |
| 2 | 2025 | Stuart Rich Chief Medical Officer | 322.7K | — | — | 3.24M | 157.5K | 10.0K | 3.73M | 86.87% | ↗ |
| 3 | 2025 | Thomas A. McGauley Interim Chief Financial Officer | — | — | — | — | — | 475.5K | 475.5K | 0.00% | ↗ |
| 4 | 2024 | Christopher T. Giordano President and Chief Executive Officer | 495.7K | — | — | 6.48M | 390.0K | 42.9K | 7.40M | 87.46% | ↗ |
| 5 | 2024 | Christopher T. Giordano President and Chief Executive Officer | 495.7K | — | — | 6.48M | 390.0K | 42.9K | 7.40M | 87.46% | ↗ |
| 6 | 2024 | Stuart Rich Chief Medical Officer | 287.8K | 75.0K | — | 2.59M | 175.0K | 10.2K | 3.14M | 82.54% | ↗ |
| 7 | 2024 | Stuart Rich Chief Medical Officer | 287.8K | 75.0K | — | 2.59M | 175.0K | 10.2K | 3.14M | 82.54% | ↗ |
| 8 | 2024 | Lawrence Hoffman Former Interim Chief Financial Officer | — | — | — | — | — | 297.0K | 297.0K | 0.00% | ↗ |
| 9 | 2024 | Thomas A. McGauley Interim Chief Financial Officer | — | — | — | — | — | 37.2K | 37.2K | 0.00% | ↗ |
| 10 | 2023 | Christopher T. Giordano President and Chief Executive Officer | 405.3K | — | — | — | 202.7K | 36.8K | 644.8K | 0.00% | ↗ |
| 11 | 2023 | Stuart Rich Chief Medical Officer | 318.0K | — | — | — | 127.2K | 36.0K | 481.2K | 0.00% | ↗ |
| 12 | 2023 | Eliot M. Lurier Former Interim Chief Financial Officer | — | — | — | — | — | 166.3K | 166.3K | 0.00% | ↗ |
| 13 | 2022 | Christopher T. Giordano President and Chief Executive Officer | 386.0K | — | — | 104.3K | 144.8K | 32.3K | 667.3K | 15.63% | ↗ |
| 14 | 2022 | Stuart Rich Chief Medical Officer | 309.0K | — | — | 52.1K | 92.7K | 14.3K | 468.1K | 11.14% | ↗ |
| 15 | 2022 | Eliot M. Lurier Former Interim Chief Financial Officer | — | — | — | — | — | 221.7K | 221.7K | 0.00% | ↗ |
| 16 | 2022 | Eliot M. Lurier Interim Chief Financial Officer | — | — | — | — | — | 221.7K | 221.7K | 0.00% | ↗ |
| 17 | 2021 | Anthony A. DiTonno Former Chief Executive Officer | 262.1K | — | — | 215.5K | 120.0K | 462.1K | 1.06M | 20.33% | ↗ |
| 18 | 2021 | Michael B. Jebsen Former President and Chief Financial Officer | 321.4K | — | — | 105.7K | 149.9K | 403.4K | 980.4K | 10.78% | ↗ |
| 19 | 2021 | Christopher T. Giordano President and Chief Executive Officer | 183.4K | — | — | 581.5K | 85.9K | 10.1K | 860.9K | 67.54% | ↗ |
| 20 | 2021 | Stuart Rich Chief Medical Officer | 287.5K | — | — | 402.8K | 115.0K | 13.0K | 818.3K | 49.22% | ↗ |
| 21 | 2021 | Eliot M. Lurier Interim Chief Financial Officer | — | — | — | — | — | 25.9K | 25.9K | 0.00% | ↗ |
| 22 | 2020 | Anthony A. DiTonno Chief Executive Officer | 440.8K | — | — | 71.7K | 221.5K | — | 733.9K | 9.77% | ↗ |
| 23 | 2020 | Anthony A. DiTonno Former Chief Executive Officer | 440.8K | — | — | 71.7K | 221.5K | — | 733.9K | 9.77% | ↗ |
| 24 | 2020 | Michael B. Jebsen, CPA President and Chief Financial Officer | 350.0K | — | — | 71.7K | 175.8K | — | 597.5K | 12.00% | ↗ |
| 25 | 2020 | Michael B. Jebsen Former President and Chief Financial Officer | 350.0K | — | — | 71.7K | 175.8K | — | 597.5K | 12.00% | ↗ |
| 26 | 2019 | Anthony A. DiTonno Chief Executive Officer | 430.0K | — | — | — | 75.3K | — | 505.3K | 0.00% | ↗ |
| 27 | 2019 | Michael B. Jebsen, CPA President and Chief Financial Officer | 339.8K | — | — | — | 59.8K | — | 399.5K | 0.00% | ↗ |
| 28 | 2018 | Michael B. Jebsen, CPA President and Chief Financial Officer | 381.5K | 175.0K | 175.0K | — | 124.3K | — | 855.8K | 20.45% | ↗ |
| 29 | 2018 | Anthony A. DiTonno Chief Executive Officer | 278.3K | — | — | 256.6K | 80.6K | 30.3K | 645.8K | 39.73% | ↗ |
| 30 | 2017 | John P. Kelley Former Chief Executive Officer | 122.4K | — | — | — | — | 512.2K | 634.6K | 0.00% | ↗ |
| 31 | 2017 | Michael B. Jebsen, CPA President and Chief Financial Officer | 420.4K | — | — | 92.6K | 82.9K | — | 595.9K | 15.53% | ↗ |
| 32 | 2017 | Michael B. Jebsen, CPA President, Interim Chief Executive Officer and Chief Financial Officer | 420.4K | — | — | 92.6K | 82.9K | — | 595.9K | 15.53% | ↗ |
| 33 | 2016 | John P. Kelley Former Chief Executive Officer | 430.0K | — | — | 373.1K | 290.3K | — | 1.09M | 34.12% | ↗ |
| 34 | 2016 | Michael B. Jebsen, CPA President, Interim Chief Executive Officer and Chief Financial Officer | 325.0K | — | — | 233.2K | 146.3K | — | 704.4K | 33.10% | ↗ |
| 35 | 2015 | John P. Kelley Chief Executive Officer | 330.0K | — | — | — | 148.5K | — | 478.5K | 0.00% | ↗ |
| 36 | 2015 | John P. Kelley Chief Executive Officer | 330.0K | — | — | — | 148.5K | — | 478.5K | 0.00% | ↗ |
| 37 | 2015 | John P. Kelley Former Chief Executive Officer | 286.7K | — | — | — | 159.0K | — | 445.7K | 0.00% | ↗ |
| 38 | 2015 | Michael B. Jebsen, CPA President, Chief Financial Officer | 285.0K | — | 2.1K | — | 128.3K | 9.6K | 425.0K | 0.50% | ↗ |
| 39 | 2015 | Michael B. Jebsen, CPA President, Interim Chief Executive Officer and Chief Financial Officer | 216.7K | — | — | — | 81.0K | — | 297.7K | 0.00% | ↗ |
| 40 | 2015 | Michael B. Jebsen, CPA President, Chief Financial Officer | 216.7K | — | — | — | 81.0K | — | 297.7K | 0.00% | ↗ |
| 41 | 2014 | Michael B. Jebsen, CPA President, Chief Financial Officer and Former Interim Chief Executive Officer | 309.4K | 225.0K | 332.2K | 3.95M | 176.2K | 9.6K | 5.01M | 85.62% | ↗ |
| 42 | 2014 | Michael B. Jebsen, CPA President, Chief Financial Officer | 309.4K | 225.0K | 332.2K | 3.95M | 176.2K | 9.6K | 5.01M | 85.62% | ↗ |
| 43 | 2014 | John P. Kelley Chief Executive Officer | 151.3K | — | — | 3.95M | 82.5K | — | 4.19M | 94.42% | ↗ |
| 44 | 2014 | John P. Kelley Chief Executive Officer | 151.3K | — | — | 3.95M | 82.5K | — | 4.19M | 94.42% | ↗ |
| 45 | 2013 | Michael B. Jebsen, CPA President, Chief Financial Officer and Former Interim Chief Executive Officer | 330.0K | — | 60.3K | — | — | 9.6K | 399.9K | 15.08% | ↗ |
| 46 | 2013 | Michael B. Jebsen, CPA President, Interim Chief Executive and Chief Financial Officer | 330.0K | — | 60.3K | — | — | 9.6K | 392.8K | 15.35% | ↗ |
| 47 | 2012 | Michael B. Jebsen, CPA President, Interim Chief Executive and Chief Financial Officer | 295.0K | — | 16.9K | — | 105.0K | 9.6K | 426.5K | 3.95% | ↗ |
| 48 | 2012 | Chris J. Stern Chairman and Chief Executive Officer | 111.7K | — | 228.9K | — | — | 3.2K | 343.9K | 66.58% | ↗ |
| 49 | 2012 | Dr. Gerald Klein Chief Medical Officer | 114.0K | — | 14.7K | 56.8K | — | 4.0K | 189.5K | 37.74% | ↗ |
| 50 | 2011 | Chris J. Stern Chairman and Chief Executive Officer | 300.0K | — | 29.1K | — | 131.0K | 9.6K | 469.7K | 6.20% | ↗ |
| 51 | 2011 | Chris J. Stern Former Chairman and | 300.0K | — | 29.1K | — | 131.0K | 9.6K | 469.7K | 6.20% | ↗ |
| 52 | 2011 | Michael B. Jebsen, CPA President, Interim Chief Executive and Chief Financial Officer | 210.0K | — | — | 42.7K | 70.0K | 9.6K | 332.3K | 12.86% | ↗ |
| 53 | 2011 | Michael B. Jebsen, CPA President, Interim Chief Executive and Chief Financial Officer | 210.0K | — | — | 42.7K | 70.0K | 9.6K | 332.3K | 12.86% | ↗ |
| 54 | 2011 | Dr. Richard Kiral Former President and | 235.9K | — | — | 29.4K | — | 29.4K | 294.7K | 9.99% | ↗ |
| 55 | 2011 | Dr. Gerald Klein Chief Medical Officer | 172.4K | — | 22.3K | — | 75.0K | 24.4K | 294.1K | 7.57% | ↗ |
| 56 | 2011 | Dr. Gerald Klein Chief Medical Officer | 172.4K | — | — | 22.3K | 75.0K | 24.4K | 294.1K | 7.57% | ↗ |
| 57 | 2010 | Chris J. Stern Former Chairman and | 300.0K | — | 160.2K | — | 100.0K | 9.6K | 569.8K | 28.12% | ↗ |
| 58 | 2010 | Dr. Richard Kiral Former President and | 247.0K | — | 43.2K | 74.0K | 80.3K | 9.6K | 454.1K | 25.82% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher T. Giordano | Chief Executive Officer, President & Director | 813.6K | male |
| Stuart Rich | Chief Medical Officer & Director | 490.2K | — |
| Thomas A. McGauley | Interim Chief Financial Officer and Principal Financial Officer & Principal Accounting Officer | 475.5K | male |
| Doug Randall | Chief Business Officer | — | male |
| Douglas Hay | Executive Vice President of Regulatory Affairs | — | — |
| Timothy G. Healey | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TENX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
